HOTH THERAPEUTICS INC (HOTH)       0.4513  +0 (+0.29%)

0.4513  +0 (+0.29%)

US44148G1058 - Common Stock - After market: 0.4699 +0.02 (+4.12%)


Fundamental Rating

Overall HOTH gets a fundamental rating of 3 out of 10. We evaluated HOTH against 264 industry peers in the Pharmaceuticals industry. HOTH scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. HOTH has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating


The Piotroski-F score of HOTH is 4.00. This is a neutral score and indicates average health and profitability for HOTH.
HOTH has negative profitability rations, so we won't be analyzing them here.

HOTH's Return On Assets of -141.12% is worse than the rest of the industry. The industry average Return On Assets is -37.76%. 94% of the industry peers have a better Return On Assets.
VS Industry

ROA (-141.12%) VS Industry: 6% outperformed.

-838.18
51.98

Valuation

Valuation Rating


When comparing the current price to the book value of HOTH, we can conclude it is valued correctly. It is trading at 1.84 times its book value.
When comparing the price book ratio of HOTH to the average industry price book ratio of 1.95, HOTH is valued in line with its industry peers.

The Price/Earnings Ratio is negative for HOTH. In the last year negative earnings were reported.
Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (1.84) VS Industry: 51% outperformed.

128.04
0.18

Growth

Growth Rating


The Earnings Per Share has grown by an nice 17.19% over the past year.

HOTH is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 3.89% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 17.19% 37.41% 18.86% 9.32% 3.89%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating


A Current Ratio of 10.34 indicates that HOTH has no problem at all paying its short term obligations.
HOTH is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 4.17.
A Quick Ratio of 10.34 indicates that HOTH has no problem at all paying its short term obligations.
When comparing the Quick Ratio to an average industry Quick Ratio of 3.66, HOTH is better placed than the average industry peer to meet its short term obligations.

The Debt to Equity ratio of HOTH is in line with the industry averages.
HOTH has a Altman-Z score comparable to the industry average, which is at -0.05.
The Piotroski-F score of HOTH is 4.00. This is a neutral score and indicates average health and profitability for HOTH.
HOTH has an Altman-Z score of -0.74. This is a bad value and indicates that HOTH is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (0) VS Industry: 50% outperformed.

16.87
-107.26

Quick Ratio (10.34) VS Industry: 78% outperformed.

0.02
201.08

Current Ratio (10.34) VS Industry: 78% outperformed.

0.02
201.08

Altman-Z (-0.74) VS Industry: 45% outperformed.

-228.66
634.81

Dividend

Dividend Rating


HOTH does not give a dividend.

HOTH Daily chart

HOTH THERAPEUTICS INC0.4513

NASDAQ:HOTH (8/10/2022, 7:00:02 PM)+0 (+0.29%)

After market: 0.4699 +0.02 (+4.12%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 05-12 2022-05-12/amc Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 4.3%
Market Cap 14.54M Analysts 82.5
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 1.84
EV/EBITDA -0.55
Profitability
ROA -141.12% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y 17.19% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 54.17%
EPS Next Y 37.41% EPS Next 2Y 18.86%
EPS Next 3Y 9.32% EPS Next 5Y 3.89%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 10.34 Quick Ratio 10.34
Altman-Z -0.74 F-Score 4
Debt/Equity N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA